Introduction {#Sec1}
============

Cellulitis is a common bacterial skin infection that involves the lower extremities in \>70% of cases \[[@CR1], [@CR2]\]. Recurrences are frequent affecting 15--40% of patients in the first 3 years and constitute a significant risk factor for further disease episodes \[[@CR1], [@CR3]\]. Common causative agents comprise Gram-positive aerobes, particularly *Streptococci* (groups A, B, C and G) and *Staphylococcus aureus* \[[@CR2], [@CR4]\]. Widely used recommendations for initial empirical treatment include short schemes (5--10 days) with beta-lactam antimicrobials \[[@CR2]\].

This retrospective case series reports a reasonably low recurrence rate in patients treated with a 3-week sequential daptomycin-roxithromycin scheme for the initial lower limb cellulitis episode.

Methods {#Sec2}
=======

Adult patients hospitalized in the Dermatology Clinic of the Ioannina University Hospital between January 2008 and December 2011 for the first episode of community-acquired lower limb cellulitis were treated sequentially with intravenous daptomycin (4 mg/kg/day; Cubicin^®^, Novartis Pharmaceuticals, UK, Ltd) during hospitalization and roxithromycin per os (2 × 150 mg daily; Rulid^®^, Sanofi-Aventis A.E.B.E., Greece) for a total of three weeks. Cases requiring hospitalization (for treatment strategy of patients with cellulitis in this hospital see also \[[@CR3]\]) were defined as patients with clinical findings of cellulitis (unilateral, relatively demarcated area of expanding skin inflammation, with malaise, fever or chills) and an abnormal result in at least one of the following tests: total white blood cell (WBC) count (normal range: 4500--10,500 cells/μL), serum C-reactive protein (CRP) level (normal range \<6 mg/L) or erythrocyte sedimentation rate (ESR; normal range \<20 mm/h). Only patients who completed treatment were considered in the recurrences analysis. Primary study end-point was the rate of recurrences during follow-up after treatment, that is, cellulitis in the same lower limb diagnosed more than 1 month after treatment of the first disease episode. Recurrences were identified by (1) hospital records (archived patients' files) of cellulitis admissions and (2) telephone questionnaires conducted in February 2012 and February 2015. Recurrence rates and their binomial 95% confidence intervals (CIs) were calculated with SPSS 22.0 software package (SPSS Inc., Chicago, IL, USA). Moreover, employing the mean individualized 2 years follow-up recurrence probabilities of lower leg cellulitis according to the prognostic model of McNamara et al. \[[@CR5]\] an anticipated recurrence rate was calculated for the present case series. For this study University Hospital of Ioannina Ethics and Clinical Trials Review Committee permission was granted according to the Declaration of Helsinki Principles.

Results {#Sec3}
=======

Twenty-seven patients were started on intravenous daptomycin and 26 patients (15 male, 11 female; median age 68 years, range 38--89 years) who completed treatment were followed up for recurrences. Depending on the individual disease course the patients received daptomycin for 7--14 days. One patient with inadequate clinical cellulitis control at 48 h after treatment initiation was excluded from follow-up: treatment failure rate of daptomycin 3.7%. In the case of this single non-responder cure was achieved by adding intravenous ceftriaxone (2 g/day; Rocephin^®^, Roche Hellas A.E.) to the treatment scheme. After 37--85 months follow-up one recurrence occurred, that is, 96.2% of the patients remained relapse-free at the end of follow-up (95% CI 79.5--99.9%). The recurrence occurred in a 70-year-old female patient with a left tibia cellulitis and history of breast cancer (see Table S1 in the supplementary material for a compilation of core cohorts' demographic and disease parameters). It is worth noting that the predicted recurrence free rate at 2 years follow-up according to McNamara's recurrence score for lower leg cellulitis (73.5%) is outside the 95% confidence range of the recurrence rate observed in the present case series. However, instead of the 2-year period of the above model we presently considered follow-up periods \>3 years. Finally, considering overall effectiveness of the treatment, 25/27 patients initially treated with daptomycin for the first lower leg cellulitis episode (92.6%; 95% CI 75.5--99.0%) remain recurrence free after more than 3 years follow-up.

Discussion {#Sec4}
==========

With the present three-week treatment combination, in addition to a satisfactory (\>95%) cure rate, we observed an optimistic low disease recurrence rate after more than 3 years follow-up. The present observation further supports our recent finding that the treatment of the first cellulitis episode with a 3 week clindamycin scheme may reduce the risk of subsequent recurrences \[[@CR3]\]. Compared to conventional treatment selections cure rate of cellulitis with daptomycin are not inferior and due to once daily bolus administration, this agent could be also suitable for outpatient parental antibiotic therapy \[[@CR6], [@CR7]\].

The pathogenesis of recurrent cellulitis episodes is still poorly understood \[[@CR1], [@CR2]\]. Recurrent episodes of cellulitis generate functional residua in the affected skin area that predispose to subsequent disease episodes, thus creating a vicious cycle. To date the concept of modifying cellulitis recurrence risk by the selection of different treatment schemes for the first disease episode has not been adequately addressed. However, the treatment choice for the first cellulitis episode may confer protection against the risk of future relapses by different mechanisms: (1) Targeting bacterial protein synthesis by the antibacterial scheme could inhibit toxin synthesis and inflammatory mediators production during infection and thus protect tissues from excess damage (e.g., lymphedema perpetuation) \[[@CR3], [@CR4]\]; (2) prolonged treatment duration (\>2 weeks) may effectively eradicate latent infection foci in the relatively immunocompromised compartment of the tibial skin \[[@CR8], [@CR9]\]; (3) It is further conceivable that the pathogenetic potential of the infecting bacterial strain, as denoted by the species and subspecies status, could variably predispose to subsequent relapses \[[@CR10]\]. Daptomycin and roxithromycin target a broader species spectrum than traditional beta-lactam antibacterials.

This may be the first report of a long-term follow-up for recurrences in patients who were started on daptomycin for the first cellulitis episode. This study is limited by retrospective planning and the restricted number of included patients. Future studies should explore interventions for the first cellulitis episode as a means to modify the risk of the frequently detrimental recurring course of this disease.
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